Form 4: KalVista Pharmaceuticals Director Acquires Stock Options

Director Edward W Unkart acquired stock options for 10,000 shares of KalVista Pharmaceuticals, Inc. on October 3, 2024.

Summary

• On October 3, 2024, Edward W Unkart, a director of KalVista Pharmaceuticals, Inc., acquired stock options for 10,000 shares.
• The options have an exercise price of $11.54.
• The options vest over a 12-month period, starting November 3, 2024, with 1/12th of the total shares vesting monthly, contingent upon continued service.
• The options expire on October 2, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but the vesting schedule implies continued service is expected.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates